…
Jushi Holdings Inc. engages in the retail, distribution, cultivation, and processing of cannabis for medical and adult-use markets in the United States. The company offers flower, vapes, concentrates, infused chews and chocolates, tinctures, capsules, softgels, topicals and RSO, pre-rolls, and infused chocolate bites under the Hijinks, The Bank, The Lab, Tasteology, Uncommon Kind, Nira + Medicinals, Sèche, Shayo, and Carm's Delight Bites brands. It also engages in the sale of bulk raw materials to duly licensed third parties for use in its own finished products. In addition, the company operates medical cannabis dispensaries under the Beyond Hello, Nature's Remedy, and NuLeaf brands. It serves small local dispensaries and large multi-state operators. Jushi Holdings Inc. was founded in 2018 and is headquartered in Boca Raton, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Jushi Holdings is a U.S. multi-state cannabis company that cultivates, manufactures and sells cannabis and hemp-derived products through wholesale channels and branded dispensaries. Long-term growth may be driven by expanding retail footprint, broader product offerings and production scale that could support margins; investors may find it attractive for a multi-state operating model and consumer-focused brands that could diversify revenue.
Material risks include federal/state regulatory uncertainty, constrained banking and capital access, intense competition and execution risk around licensing and store openings.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -33.60M | -17.15M | -33.30M | -193.88M | 52.45M |
| Minority interest | - | - | 0.00M | 0.00M | 2.77M |
| Net income | -68.59M | -48.78M | -65.10M | -202.32M | 24.14M |
| Selling general administrative | 78.26M | 79.08M | 84.10M | 156.17M | 101.69M |
| Gross profit | 113.98M | 118.30M | 116.23M | 95.48M | 87.37M |
| Reconciled depreciation | 30.99M | 29.89M | 26.59M | 26.49M | 9.47M |
| Ebit | - | - | - | -148.28M | -29.07M |
| Ebitda | - | - | - | -121.65M | 93.12M |
| Non operating income net other | - | - | - | 72.05M | - |
| Operating income | 2.18M | 8.89M | 4.13M | -220.33M | -21.16M |
| Interest expense | 41.30M | 37.98M | 37.06M | 45.59M | 31.20M |
| Tax provision | 34.99M | 31.63M | 31.81M | 8.45M | 31.09M |
| Interest income | 0.46M | 0.56M | 0.09M | 0.14M | 0.24M |
| Net interest income | -40.84M | -37.42M | -36.97M | -45.59M | -30.96M |
| Non recurring | - | - | - | 159.65M | - |
| Income tax expense | - | - | - | 8.45M | 29.62M |
| Total revenue | 262.91M | 257.52M | 269.44M | 284.28M | 209.29M |
| Total operating expenses | 260.73M | 248.63M | 265.32M | 315.81M | 230.45M |
| Cost of revenue | 148.93M | 139.22M | 153.22M | 188.81M | 121.92M |
| Total other income expense net | 5.07M | 11.38M | -0.46M | -87.60M | 104.57M |
| Net income from continuing ops | -68.59M | -48.78M | -65.10M | -202.32M | 21.36M |
| Net income applicable to common shares | - | - | - | -202.32M | 20.25M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 422.34M | 440.32M | 463.39M | 529.34M | 677.91M |
| Intangible assets | 92.20M | 100.47M | 95.97M | 100.08M | 182.47M |
| Other current assets | 2.11M | 1.79M | 1.01M | 3.96M | 1.68M |
| Total liab | 537.69M | 490.56M | 471.01M | 483.45M | 494.82M |
| Total stockholder equity | -115.34M | -50.23M | -7.62M | 47.28M | 184.48M |
| Deferred long term liab | - | - | - | 14.13M | - |
| Other current liab | 0.30M | - | 3.23M | 11.36M | 20.52M |
| Common stock | - | - | - | - | 424.79M |
| Capital stock | 511.87M | 508.39M | 503.61M | 492.02M | 427.32M |
| Retained earnings | -627.21M | -558.62M | -509.84M | -444.74M | -242.42M |
| Other liab | - | - | - | 77.34M | 163.88M |
| Good will | 30.91M | 30.91M | 30.91M | 38.24M | 75.33M |
| Other assets | - | - | - | 11.97M | 9.32M |
| Cash | 24.05M | 19.52M | 26.03M | 26.20M | 94.96M |
| Total current liabilities | 66.19M | 68.89M | 162.46M | 107.63M | 83.93M |
| Net debt | 181.79M | 166.69M | 186.53M | 163.07M | 32.26M |
| Short term debt | - | - | - | 8.70M | - |
| Short long term debt | 6.64M | 2.76M | 86.51M | 8.70M | 2.11M |
| Other stockholder equity | - | - | - | - | 24.96M |
| Property plant equipment | - | - | - | 177.75M | 248.58M |
| Total current assets | 68.31M | 72.15M | 81.64M | 70.05M | 154.36M |
| Long term investments | - | 0.00M | 0.20M | 0.98M | 1.50M |
| Net tangible assets | - | - | - | -91.04M | -55.92M |
| Short term investments | - | - | - | - | 0.00M |
| Net receivables | 2.80M | 1.46M | 3.38M | 4.81M | 10.56M |
| Long term debt | 199.19M | 183.45M | 126.04M | 180.56M | 125.11M |
| Inventory | 34.61M | 36.14M | 33.59M | 35.09M | 43.32M |
| Accounts payable | 22.33M | 21.46M | 15.38M | 87.56M | 18.55M |
| Noncontrolling interest in consolidated entity | - | - | - | -1.39M | - |
| Retained earnings total equity | - | - | - | -444.74M | - |
| Non currrent assets other | 2.97M | 6.79M | 9.13M | 143.21M | 3.67M |
| Non current assets total | 354.03M | 368.17M | 381.76M | 459.29M | 514.60M |
| Capital lease obligations | 87.57M | 84.92M | 86.28M | 131.94M | 118.87M |
| Long term debt total | - | - | - | 180.56M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | -5.21M | -13.80M | -80.86M | 9.15M |
| Change to liabilities | - | - | - | 24.11M | 21.56M |
| Total cashflows from investing activities | - | - | - | -80.86M | -113.45M |
| Net borrowings | 2.65M | -21.44M | 13.29M | -8.51M | 36.58M |
| Total cash from financing activities | 0.77M | -24.46M | 15.12M | 33.98M | 137.66M |
| Change to operating activities | - | - | - | 3.36M | -3.90M |
| Net income | -68.59M | -48.78M | -65.10M | -202.32M | 20.25M |
| Change in cash | 5.27M | -9.96M | -1.54M | -68.29M | 9.63M |
| Begin period cash flow | 21.35M | 31.30M | 32.01M | 95.49M | 85.86M |
| End period cash flow | 26.62M | 21.35M | 30.29M | 27.15M | 95.49M |
| Total cash from operating activities | 17.73M | 21.57M | -3.04M | -21.42M | -14.30M |
| Issuance of capital stock | - | - | 0.00M | 13.68M | 85.66M |
| Depreciation | 30.99M | 29.89M | 30.61M | 45.93M | 8.41M |
| Other cashflows from investing activities | - | - | - | -23.98M | -3.00M |
| Dividends paid | - | - | - | - | 0.00M |
| Change to inventory | 1.76M | -4.01M | -11.53M | 5.40M | -12.95M |
| Change to account receivables | -1.13M | 1.86M | -3.04M | -1.59M | -1.87M |
| Sale purchase of stock | - | - | - | 13.68M | - |
| Other cashflows from financing activities | - | - | - | 28.81M | -1.70M |
| Change to netincome | - | - | - | 121.17M | -45.81M |
| Capital expenditures | 17.29M | 4.71M | 16.04M | 56.88M | 75.30M |
| Change receivables | - | - | - | -1.59M | - |
| Cash flows other operating | - | - | - | 10.01M | - |
| Cash and cash equivalents changes | - | - | - | -68.29M | - |
| Change in working capital | 2.67M | 6.19M | -5.37M | 31.27M | 37.55M |
| Stock based compensation | 2.10M | 4.22M | 11.69M | 23.07M | 13.41M |
| Other non cash items | 13.76M | 9.26M | 30.38M | 40.36M | 22.55M |
| Free cash flow | 0.43M | 16.86M | -19.08M | -78.30M | -72.74M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MKKGY Merck KGaA ADR |
-0.74 2.19% |
33.06 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
170.05 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.34 1.66% |
21.18 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.72 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Jushi Holdings Inc. engages in the retail, distribution, cultivation, and processing of cannabis for medical and adult-use markets in the United States. The company offers flower, vapes, concentrates, infused chews and chocolates, tinctures, capsules, softgels, topicals and RSO, pre-rolls, and infused chocolate bites under the Hijinks, The Bank, The Lab, Tasteology, Uncommon Kind, Nira + Medicinals, Sèche, Shayo, and Carm's Delight Bites brands. It also engages in the sale of bulk raw materials to duly licensed third parties for use in its own finished products. In addition, the company operates medical cannabis dispensaries under the Beyond Hello, Nature's Remedy, and NuLeaf brands. It serves small local dispensaries and large multi-state operators. Jushi Holdings Inc. was founded in 2018 and is headquartered in Boca Raton, Florida.
| Name | Title | Year Born |
|---|---|---|
| Mr. James Anthony Cacioppo | Founder, Chairman & CEO | 1963 |
| Mr. Louis Jonathan Barack | Founder, Pres, Corp. Sec. & Interim CFO | 1978 |
| Mr. Erich Mauff | Founder & Consultant | 1967 |
| Mr. Leonardo Garcia-Berg | Chief Operations Officer | 1965 |
| Mr. Trenton Woloveck | Chief Commercial Director | 1985 |
| Mr. James Cabral | Chief Accounting Exec. | NA |
| Mr. Michael Perlman | Exec. VP of Investor Relations | NA |
| Mr. Ian Farrell | VP of Compliance | NA |
| Ms. Tobi Lebowitz | Chief Legal Officer & Corp. Sec. | NA |
| Ms. Nichole Upshaw | Chief People Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.